메뉴 건너뛰기




Volumn 34, Issue 6, 2013, Pages 831-839

Drug development status for Alzheimer's disease: Present scenario

Author keywords

Alzheimer's disease; Clinical trials; Dementia; Phase I; Phase II; Phase III

Indexed keywords

(7 CHLORO N QUINUCLIDIN 3 YL)BENZO[B]THIOTHIOPHENE 2 CARBOXAMIDE; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; AVP 923; AZD 1446; BAPINEUZUMAB; BETA SECRETASE; CRENEZUMAB; DEXTROMETHORPHAN; DIMEBON; DONEPEZIL; EHT 0202; ETAZOLATE; EVP 6124; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GONADORELIN RECEPTOR; GSK 933776; ISPRONICLINE; MK 0249; NOOTROPIC AGENT; PF 4494700; PLACEBO; PONEZUMAB; PRX 03140; QUINIDINE SULFATE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RILAPLADIB; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 4896;

EID: 84879118825     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1316-x     Document Type: Review
Times cited : (30)

References (23)
  • 1
    • 48749125741 scopus 로고    scopus 로고
    • Alzheimer’s disease drug development in 2008 and beyond: Problems and opportunities
    • 18690832 10.2174/156720508785132299 1:CAS:528:DC%2BD1cXpsVylsLw%3D
    • Becker RE, Greig NH (2008) Alzheimer’s disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 5(4):346
    • (2008) Curr Alzheimer Res , vol.5 , Issue.4 , pp. 346
    • Becker, R.E.1    Greig, N.H.2
  • 2
    • 77953886784 scopus 로고    scopus 로고
    • Current status on Alzheimer disease molecular genetics: From past, to present, to future
    • 20388643 10.1093/hmg/ddq142 1:CAS:528:DC%2BC3cXmsVSrtLs%3D
    • Bettens K, Sleegers K, Van Broeckhoven C (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19(R1):R4-R11
    • (2010) Hum Mol Genet , vol.19 , Issue.R1
    • Bettens, K.1    Sleegers, K.2    Van Broeckhoven, C.3
  • 3
    • 79954473644 scopus 로고    scopus 로고
    • Neurobiological aspects of Alzheimer's disease
    • 1:CAS:528:DC%2BC3MXksV2lsr0%3D
    • Chopra K, Misra S, Kuhad A (2011) Neurobiological aspects of Alzheimer's disease. Expert OpinTher Targets 15(5):535-555
    • (2011) Expert OpinTher Targets , vol.15 , Issue.5 , pp. 535-555
    • Chopra, K.1    Misra, S.2    Kuhad, A.3
  • 4
    • 77953518555 scopus 로고    scopus 로고
    • Alzheimer's disease: Clinical trials and drug development
    • 20610346 10.1016/S1474-4422(10)70119-8 1:CAS:528:DC%2BC3cXpsFajur8%3D
    • Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9(7):702-716
    • (2010) Lancet Neurol , vol.9 , Issue.7 , pp. 702-716
    • Mangialasche, F.1    Solomon, A.2    Winblad, B.3    Mecocci, P.4    Kivipelto, M.5
  • 5
    • 77949300796 scopus 로고    scopus 로고
    • 11C-PiB PET assessment of change in fibrillar amyloid-[beta] load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study
    • 20189881 10.1016/S1474-4422(10)70043-0 1:CAS:528:DC%2BC3cXltF2kt7Y%3D
    • Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA (2010) 11C-PiB PET assessment of change in fibrillar amyloid-[beta] load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4):363-372
    • (2010) Lancet Neurol , vol.9 , Issue.4 , pp. 363-372
    • Rinne, J.O.1    Brooks, D.J.2    Rossor, M.N.3    Fox, N.C.4    Bullock, R.5    Klunk, W.E.6    Mathis, C.A.7    Blennow, K.8    Barakos, J.9    Okello, A.A.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.